Regulatory Post Marketing Surveillance of Prezista 400mg Tablet

Trial Profile

Regulatory Post Marketing Surveillance of Prezista 400mg Tablet

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Dec 2016

At a glance

  • Drugs Darunavir (Primary) ; Ritonavir
  • Indications HIV infections
  • Focus Adverse reactions
  • Sponsors Janssen
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 14 Oct 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top